Lidocaine for Diabetic Peripheral Neuropathy

• Status: Completed
• Trial end date: 2018-10-17
• Target enrollment: 0
• Participant gender: All

Summary

Diabetic nerve pain [painful diabetic peripheral neuropathy] is a common medical problem with few reliably effective treatments. There is some evidence that sensory testing may help determine how individuals will respond to analgesic therapy. In this study, the investigators are evaluating the relationship between sensory testing and subject response to lidocaine infusion therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Lidocaine

Criteria

Inclusion Criteria:

1. Age ≥18;

2. Diagnosis of Diabetes Mellitus (Fasting Plasma Glucose > 126 mg/dL and/or HbA1C >6.5%);

3. Distal symmetric pain in lower extremities with duration of more than 3 months;

4. Presence of either numbness or at least 1 sensory disturbance (increased or decreased sensitivity) in the feet.

5. Spontaneous pain with intensity of ≥ 4 on 0-10 Numerical Rating Scale (NRS).

Exclusion Criteria:

1. Not giving consent to participate in the study;

2. Unable to complete self-report pain questionnaire;

3. History of moderate to severe renal or liver failure;

4. History of other central or peripheral neurologic disorders;

5. History of cardiac arrhythmias;

6. Contraindication to intravenous lidocaine;

7. Pregnancy or lactation.